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Immunotherapy is moving to the forefront of cancer treatments owing to impressive
durable responses achieved with checkpoint blockade antibodies and adoptive T-cell
therapy. Still, improvements are necessary since, overall, only a small percentage
of patients benefit from current therapies. Here, I summarize evidence that DGK-α
may represent an immunological checkpoint suppressing the activity of cytotoxic
immunocytes in the tumor microenvironment. DGK-inhibitors can restore the antitumor
function of tumor-suppressed adaptive and innate cytotoxic immunocytes. The activity
of DGK-inhibitors lays downstream of current checkpoint blockade antibodies. Thus,
synergistic effects are expected from combination strategies. Moreover, DGK-inhibitors
may permit a double-strike attack on tumor cells as DGK-inhibition may not only
re-instate immunological tumor attack but also may harm tumor cells directly by
interfering with oncogenic survival pathways. Together, DGK-inhibitors have very
promising characteristics and may be beneficially included into the armamentarium of
cancer immunotherapeutics.
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IMMUNOTHERAPY, APPROACHING FOREFRONT OF CANCER
THERAPY, SEARCHING FOR COLLABORATION
Immunotherapy is moving to the forefront of cancer therapies with an increasing assortment
of approaches being evaluated and approved for clinical application (Callahan et al., 2016;
Papaioannou et al., 2016). Recent data document measurable improvement in patient outcome
and, in several cases, induction of durable responses even in patients with far advanced disease that
proved refractory to available therapies. The new therapies indicate a paradigmatic shift in cancer
therapy in that tumor cells are no longer direct therapeutic target, but instead, therapies are directed
toward the cells of the immune system restoring their ability to recognize and destroy tumor cells.
The immune system is ideally equipped to fight cancer as its components continuously travel
throughout the body providing surveillance; immune cells can be specifically activated against
tumors, which express antigen and are often immunogenic; and they can protect against tumor
relapse owing to their ability to acquire specific and long-lasting memory. Yet, tumors escape from
immune surveillance due to immunoediting (Dunn et al., 2004) and the development of immune
cell dysfunctions (Frey and Monu, 2006; Gajewski et al., 2006). The new cancer immunotherapies
became possible through a deeper understanding of the regulatory mechanisms that govern an
effective immune response and technological advances in T-cell cultivation, engineering and
antigen identification.
Noessner DGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition
The most advanced immunotherapeutic protocols to date
include (Figure 1): (i) adoptive T-cell therapies, using ex-vivo-
expanded autologous T cells isolated from tumor tissue (TILs)
or autologous T cells engineered with therapeutic T-cell receptors
(TCRs) or chimeric antigen receptors (CARs) recognizing tumor-
expressed antigens; (ii) vaccination using tumor antigens or
tumor antigen-presenting dendritic cells to stimulate the patient’s
immune system to generate tumor-reactive T cells in situ; and
(iii) antibody-based therapies blocking immune checkpoints that
would naturally elicit negative signals that hold back T cells to
prevent autoimmune attack (Pardoll, 2012; Sharma and Allison,
2015).
While vaccination has yet to yield measurable clinical
response (van der Burg et al., 2016), high and often long-
lasting response rates are achieved with adoptive TIL therapy
(Rosenberg and Restifo, 2015) and CD19-directed CAR-T cell
therapy (Fesnak et al., 2016; Park et al., 2016). Yet, despite
its high promises, adoptive T-cell therapy still faces significant
hurdles to become one of the mainstay cancer therapies: TIL
therapy is limited to tumor entities from which sufficient TILs
can be procured [mainly melanoma and renal cell cancer
(RCC)] and TCR- or CAR-T-cell therapy requires the knowledge
FIGURE 1 | Processes to activate T cell immunity against cancer: In the lymph node, T cell priming occurs through mature dendritic cells (DCs)
presenting tumor-derived antigens. The number of arising T helper (TH) cells and cytotoxic T cells (CTL) is limited through cytotoxic T-lymphocyte-associated
antigen-4 (CTLA-4). Antibodies against CTLA-4 allow for activation of more T cells due to the amelioration of negative signals during T-cell priming. In addition,
anti-CTLA-4 inhibits Treg which express high levels of CTLA-4 constitutively. Activated T cells migrate into the tumor milieu where they engage with tumor cells
expressing peptide-MHC that can be recognized by the T cell receptor (TCR). TCR-pMHC interaction will activate tumor cell killing processes unless suppression
occurs through concomitant PD-1/PD-L1 interaction. Killing of tumor cells can occur if the negative signaling is blocked through anti-PD-1 or anti-PD-L1 antibodies.
NK cells can recognize tumor cells that express low or no MHC and, thus, cooperate with CTL to prevent tumor escape. If tumor cell killing occurs, antigen is released
which can be taken up by immature DCs. Immature DCs can mature to mature DCs which then present antigen to T cells in the lymph node, leading to the generation
of new tumor-reactive T cells. If the natural process of antigen presentation does not occur (efficiently), therapeutic vaccination using ex vivo generated antigen-loaded
DCs or peptides may be applied.
of tumor-specific antigens to which T cells can be safely
directed without harming vital organs. Currently, CAR-therapy
is restricted to leukemia and lymphoma that express CD19 as
targetable antigens. Treatment of solid tumors is explored, such
as glioblastoma expressing a mutant form of the epidermal
growth factor (EGFRvIII) or adenocarcinoma expressing cancer-
associated glycoforms of mucin (Newick et al., 2016; Posey et al.,
2016). Moreover, safety issues need to be resolved since serious
adverse effects have been reported in TCR- and CAR-therapy
trials (Gross and Eshhar, 2016).
Contrasting the currently limited application of adoptive
T-cell therapy, immunotherapy with checkpoint blockade
antibodies has achieved exciting results across a wide variety of
cancer entities, not limited to commonly assumed immunogenic
tumors such as melanoma or RCC, but also in lung cancer,
bladder cancer or head and neck cancer. Three checkpoint
blockade antibodies are currently in the clinic. One targets the
cytotoxic T-lymphocyte-associated protein (CTLA)-4 (Postow
et al., 2015; Sharma and Allison, 2015), which is an intrinsic
negative regulator of T-cell activation during T-cell priming.
The other two antibodies target the programmed death (PD)
pathway through binding to the PD-1 protein or its ligand PD-L1.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 2 March 2017 | Volume 5 | Article 16
Noessner DGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition
The PD-1/PD-L1 checkpoint is an extrinsic “off” signal that
is operative in peripheral tissues turning off T-cell function to
help control local inflammatory responses and maintain self-
tolerance. Impressive durable responses have been observed
using anti-CTLA-4 and anti-PD-1 resulting in their approval
for the treatment of several cancers (Callahan et al., 2016).
Yet, it has to be recognized that, overall, only a minority of
patients experience substantial clinical benefit (around 15–40%
depending on the tumor entity) (Sunshine and Taube, 2015;
Ribas and Hu-Lieskovan, 2016). Improvements are necessary to
unleash the full potential of immunotherapy and to potentially
offer benefit to patients whose tumors are refractory to current
therapies.
DIACYLGLYCEROL KINASE ALPHA: A
CHECKPOINT THAT NEGATIVELY
REGULATES T-CELL FUNCTION AND
CURBS THE ACTIVITY OF CD8-T AND NK
CELLS IN THE TUMOR
MICROENVIRONMENT
T cells, in particular TH1/TC1-polarized lymphocytes, are
important players in the antitumor response. Not only is their
abundance associated with good prognosis in many tumor types
(Fridman et al., 2012), they are also required for therapeutic
response to checkpoint blockade therapy (Herbst et al., 2014;
Tumeh et al., 2014). NK cells are innate cytotoxic lymphocytes
appreciated for their ability to lyse virally infected cells as well
as tumors. They play a complementary role to CD8-T cells as
they recognize tumors which are resistant to T-cell killing due to
downregulation or loss of MHC-class I molecules (refs. in Prinz
et al., 2014). In some tumor types, such as RCC, they appear
to play a prominent role as their number is predictive of good
prognosis while that of CD8-T cells is not (Nakano et al., 2001;
Eckl et al., 2012).
While the value of the natural immune infiltrate in tumors
is appreciated, it has to be recognized that the natural immune
response is not sufficient to control tumor progression in
most cases. Various mechanisms are known that contribute
to tumor immune escape ranging from ignorance to active
suppression (Frey and Monu, 2006; Gajewski et al., 2006).
One major hurdle is the inhibition of T-cell function in the
tumor milieu. The suppressive quality of the tumor environment
not only impacts the natural immune cell infiltrate but also
curbs the efficacy of adoptive therapy, as even highly functional
in vitro engineered CAR-T cell become unresponsive in solid
tumor milieus (Janicki et al., 2008; Imai et al., 2009; Moon
et al., 2014). Recognized mechanisms are T-cell exhaustion
characterized by high expression of co-inhibitory receptors
(PD-1, LAG-3, TIM-3) (Wherry et al., 2007; Pardoll, 2012),
division arrest (Beyer et al., 2009), or effector phase inhibition
due to disruption of TCR-signaling events (Frey and Monu,
2006).
We have analyzed the dysfunctional state of CD8-T and NK
cells in human clear cell RCC (ccRCC) and observed a signature
of anergy (Prinz et al., 2012, 2014). We found that TILs were
non-responsive to stimulation, with much lower degranulation
(measured by the appearance of CD107 protein on the cell
surface), poor cytolytic activity (measured by chromium release
assay) and low cytokine production compared to CD8-T cells
and NK cells isolated from the non-tumor inflicted pole of the
kidney (NILs) or from peripheral blood (PBLs). Mechanistically,
no differences were seen activating proximal signaling molecules
(Lck, ZAP70 or PLCγ) between TILs and NILs or PBLs; however,
deficits in activating distal signaling molecules were evident.
Identified key features included high levels of diacylglycerol
kinase-α (DGK-α), low basal phosphorylation of the extracellular
signal-regulated kinase (ERK) as well as reduced stimulation-
induced phosphorylation of ERK, c-Jun N-terminal kinase (JNK)
and AKT/protein kinase B. These features were caused by
the tumor microenvironment as they were not observed in
CD8-NILs or NK-NILs, and these lymphocytes were functionally
active. The signature was similar to that previously described
for anergic CD4−T cells (Macian et al., 2002; Zheng et al.,
2008).
DGKs are appreciated as physiologic regulator of T- and
NK-cell development, differentiation and function, through
their activity to regulate the levels of DAG and phosphatidic
acid (PA), which are important second messengers in the
TCR-signaling cascade. The rasGRP/ERK pathway, activated
by DAG, is crucial for MTOC-polarization, the delivery of
lytic granules to the immunologic synapse (Quann et al., 2009)
and the subsequent lytic attack on target cells. Cytotoxicity
and production of IFN-γ, controlled among others by the
ERK-pathway, are the most important effector activities
required for tumor rejection. Thus, control of the ERK-
pathway ultimately determines a T- and NK-cell’s antitumor
activity.
In experimental systems, overexpression of DGK led to
a general attenuation of TCR-signaling as a direct result
of decreased RasGRP1/Ras/ERK-pathway activation. Moreover,
it has been shown that DGK-α and DGK-ζ , the abundant
isoforms in T cells, are necessary for establishment of
anergy (Zhong et al., 2008; Merida et al., 2015; Chen
et al., 2016). Together, these experimental findings support
our interpretation that T cells and also NK cells in the
human RCC environment are anergic, showing overexpression
of DGK-α, blunted ERK signaling and unresponsiveness
to stimulation. Observing an anergic signature in TILs of
ccRCCs is not unexpected since ccRCC is an epithelial
tumor and, thus, largely devoid of co-stimulatory ligands,
representing the classical anergy-inducing environment. Still,
we do not rule out that additional mechanisms such as
exhaustion or tolerance mediated through surface expressed
co-inhibitory molecules such as PD-1, also contribute to
functional unresponsiveness of TILs (Figure 2A). Rather, the
causes of functional unresponsiveness in the tumor milieu
are likely multifactorial. This is exemplified in an adoptive
transfer experiment using CAR-T cells (Moon et al., 2014):
in the tumor microenvironment, CAR-T cells rapidly became
hypofunctional with identified upregulation of intrinsic T-
cell inhibitory enzymes (DGK-α, DGK-ζ , SHP-1) as well as
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FIGURE 2 | Theoretical concept of combined application of checkpoint blockade therapy and DGK-inhibition. (A) Functional unresponsiveness of TILs in
the tumor milieu may have different mutually non-exclusive causes: (i) Ligation of PD-1 on T cells by tumor expressed PD-L1 may cause recruitment of phosphatase
SHP2 and subsequent dephosphorylation of the TCR proximal signal transmitter Lck as well as attenuation of AKT-signaling. Consequently, signals initiated by
TCR-peptide/MHC recognition intended to activate T-cell effector function (degranulation leading to lysis of target cells as well as IFNγ) are interrupted. The signal
interruption through PD-1/PD-L1 classically occurs as a consequence of T-cell exhaustion. (ii) Anergy is another mechanism of T-cell silencing. The underlying cause is
upregulated diacylglycerol kinase (DGK), in T cells mainly DGK-α and DGK-ζ . DGKs metabolize diacylglycerol (DAG) to phosphatidic acid (PA) lowering DAG levels
which are necessary to activate TCR distal signaling through Ras/ERK. The ERK pathway is critically import for the degranulation process that delivers lytic proteins
into the target cell for target cell death. (B) De-blocking the exhaustion pathway through checkpoint antibodies (anti-PD-1/PD-L1) releases the proximal brake at the
TCR-associated molecules (Lck- and AKT-phosphorylation); however, distal brakes through DGK may still be active (blocked ERK pathway and attenuated PKC- and
NFκB-activation) preventing full activation of the T cell‘s antitumor functions (degranulation, IFNγ). (C) Combined treatment with checkpoint antibodies and
DGK-inhibitor may be required to open the signaling cascade fully, allowing effector function.
expression of surface co-inhibitory receptors (PD-1, LAG-3,
TIM-3, 2B4).
REVERSAL OF TUMOR-INDUCED
SUPPRESSION AND RESTORATION OF
T- AND NK-CELL ACTIVITY THROUGH
DGK-INHIBITION
IL-2 is a well-known growth factor for T and NK cells and
has a history in RCC immunotherapy, achieving tumor control
in a subgroup of patients (McDermott, 2009). IL-2 is known
to regulate DGK-α and to restore functional responsiveness
of anergic CD4-T cells (Macian et al., 2002). We could show
that IL-2 restored in vivo-repressed cytokine secretion and
cytotoxicity of CD8-TILs and NK-TILs. In CD8-TILs, functional
recovery occurred concomitantly with a decrease in DGK-α and
an increase in basal and stimulation-induced phosphorylation
of key signaling proteins (ERK, AKT). In NK-TILs, IL-2 also
restored activity; here, no change in DGK-α protein was observed
suggesting direct regulation of ERK-phosphorylation, which
is in accordance to published literature (Kondadasula et al.,
2008).
We used the commercial DGK-inhibitor R-59022 and were
able to document restored degranulation of CD8-TILs and
NK-TILs, and, concomitantly, stronger ERK-phosphorylation,
thus linking DGK-α to suppressed ERK-phosphorylation and
inhibited degranulation. Of note is that the level of degranulation
of TILs in the presence of DGK-inhibition was not higher
than that observed with NK-NILs or CD8-NILs indicating
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that DGK-inhibition can restore suppressed degranulation but
does not augment degranulation beyond an NK or T cell’s
intrinsic response efficacy. This finding helps alleviate concerns
about potentially unleashing undesirable autoimmunity through
DGK-inhibition, which is an important issue when considering
potential targeting of DGK in a clinical setting.
DGK-INHIBITORS TO COLLABORATE FOR
EFFECTIVE CANCER IMMUNOTHERAPY
DGKs, expressed in T and NK cells, are attractive targets
for immunotherapy considering their physiologic function in
regulating strength and duration of signaling cascades important
for T- and NK-cell function. Observing that DGK-α and
DKG-ζ are exploited by cancer cells to suppress the activity
of cytotoxic immunocytes in the tumor microenvironment
encourages the idea that DGK-inhibitors might enrich the
current cancer immunotherapy armamentarium. Indeed, in
experimental settings, T- and NK-cell activity can be enhanced
and anergy development can be prevented through deletion or
inhibition of DGK-α or DGK-ζ (Riese et al., 2011, 2013, 2016;
Martínez-Moreno et al., 2012; Yang et al., 2016). Our results
with TILs from human RCC further suggest that DGK-inhibition
may not only prevent development of unresponsiveness but
may also be able to restore activity of suppressed immune cells.
Importantly, DGK-α inhibition can restore the function of CD8-
T cells and NK cells. NK cells can destroy tumor cells with low
or no MHC-class I proteins that may develop as escape variants
after successful T-cell therapy and can be the cause of treatment
failure. Development of escape variants may well be prevented in
therapeutic settings that activates andmaintains NK-cell function
conjointly to the activation of a T-cell response (Fruci et al., 2013).
The multifactorial nature of tumor-induced unresponsiveness
necessitates the application of multiple means to fully unleash
the power of immunotherapy. Anergy has to be recognized as
part of the inactivation process and, DGKs as its mediators,
should be considered as an additional checkpoint controlling
T-cell and NK-cell function, in addition to the currently
appreciated co-inhibitory checkpoints (PD-1, LAG-3, TIM-3,
CTLA-4) (Figure 2A). The classical co-inhibition molecules
interrupt the signaling cascade at proximal steps (Lck, ZAP70,
PI3K/AKT), while anergy-associated blockades are located
further downstream. Thus, when co-inhibition is therapeutically
alleviated through anti-PD-1/PD-L1 or anti-CTLA-4, signaling
will still be halted by paucity of DAG through high DGKs
(Figure 2B). Thus, if T-cell non-responsiveness (also) involves
high DGK, it is expected that releasing distal signaling
blockades, i.e., through DGK-inhibition, is required in addition
to checkpoint blockade therapy to fully reverse T-cell suppression
(Figure 2C). Currently, the combined application of checkpoint
antibodies and DGK-inhibition is a theoretical concept and
awaits supportive data from experimental models.
DGK-inhibition may further improve immunotherapy
considering that CAR-T cells lacking DGK-ζ were found to
be resistant to the suppressive cytokine TGF-ß (Riese et al.,
2013; Arumugam et al., 2015). The molecular basis for the
cross-talk between the two signaling cascades remains to be
resolved. One explanation could be a digital conversion of
ERK-phosphorylation to function, whereby function is enabled
if ERK-phosphorylation is above a certain threshold (outlined
also by Prinz et al., 2012). Higher ERK-phosphorylation reached
through DGK-inhibition may enable T cells to maintain
phospho-ERK levels above the threshold required for function in
the presence of other suppressive signals.
FURTHER CONSIDERATIONS FOR THE
DEVELOPMENT OF DGK-INHIBITION FOR
IMMUNOTHERAPY
DGK-inhibition has promising feature for immunotherapy. T
and NK cells express two isoforms, DGK-α and DGK-ζ , which
both regulate effector-lymphocyte function through controlling
DAG-abundance. Will it thus suffice to inhibit only one isoform
to help T and NK cells maintain function in the tumor milieu, or
is the inhibition of both required?
DGK-α and DGK-ζ activities are comprehensively discussed
in recent reviews, and thus are only briefly touched here
(Merida et al., 2015; Chen et al., 2016; Singh and Kambayashi,
2016). As specific inhibitors of DGK-ζ are not available, the
issue which one of the isoforms or whether both should
be preferably inhibited to support T and NK cells in the
tumor microenvironment cannot be adequately addressed at the
moment. Data generated with knock-out mice are of limited
information concerning effects of DGKs in the effector phase
of the immune response since disturbances in the development,
in particular observed development of hyporesponsive NK cells
and altered development of regulatory T cells (Tregs), may
obscure effects that DGK-inhibition might have when applied to
the already developed immune system. Inhibition experiments
need to be performed using immune cells from the tumor
environment, since here the immune escape processes are
manifested that are the target of immunotherapy. For clinical
extrapolation, experiments need to utilize human immune cells
as significant differences exist, previously discussed by us and
others (Prinz et al., 2012; Moon et al., 2014). Anergy-inducing
conditions might arise much more frequently in humans, since
CD8-T cell effector differentiation causes CD28 loss in humans
(but not in mouse) which deprives human CD8-T cells from
receiving co-stimulation. This may moderate the extent to
which DGK-α or DGK-ζ participates in the regulation of DAG-
mediated pathways in human and mouse models.
Different structural designs of DGK-α and DKG-ζ and
accordingly different modes of activation allow some speculation
as to which isoform possibly contributesmore to the regulation of
DAG-mediated signals in a specific situation. DGK-α, containing
a calcium-binding EF-hand motif, is activated through Ca2+
ions, in addition to Lck-mediated phosphorylation, while DKG-
ζ , lacking the calcium-binding EF motif, is not responsive
to calcium signals and is activated through protein kinase C
(PKC)-mediated phosphorylation. In physiologic situation where
TCR-activation occurs concomitantly with co-stimulation, DKG-
ζ may play the dominant role. In situations, however, where
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the co-stimulatory pathway is not provided, DGK-α will be
disproportionally activated through Ca-induced conformational
changes and Lck-dependent phosphorylation. TCR-stimulation
without co-stimulation commonly occurs during effector phase
activation of CD8-T cells in epithelial tissue or carcinomas due to
the paucity of CD28 on human CD8-T effector cells and the lack
of co-stimulatory ligands in epithelial tissues. Evidence for this
scenario is seen in TILs of RCC that failed to activate the AKT
pathway after TCR-stimulation while Lck- and PLCγ-activation
occurred normally. Thus, the necessary signals (Lck, Ca2+) for
DGK-α-activation are provided, with ensuing depletion of DAG
and attenuation of effector activity. Extending on this, one might
speculate that DGK-α is more relevant isoform to be targeted in
cancer immunotherapy.
However, DKG-ζ was not analyzed in TILs due to the lack
of specific reagents. Results from adoptive transfer studies using
human CAR-T cells showed that DGK-α and DKG-ζ were
upregulated in hyporesponsive CAR-T cells recovered from the
tumor milieu of human xenografts (Moon et al., 2014). Here
again DGK-ζ specific inhibition was not performed; thus, it
remains to be addressed to which extent DKG-ζ overexpression
contributed to the hypofunctional state of the CAR-T cells.
Considering DGK-inhibition for cancer immunotherapy
attention should also be given to possible effects on other
immune cells in the tumor microenvironment and the
cancer cells themselves. DGK-α and DGK-ζ have effects on
macrophages, dendritic cells and Tregs (Singh and Kambayashi,
2016). In macrophages and dendritic cells, DKG-ζ deficiency was
found to be associated with impaired secretion of inflammatory
IL-12 and TNF and impaired Th1-responses. Both isoforms
were reported to inhibit the suppressive activity of Tregs.
Considering the required function of myeloid cells and Tregs in
antitumor response, DGK-inhibition (independent of isoform)
may not yield desirable outcome. However, it has to be noted
that none of the experiments were performed with tumor-
educated cell types, thus the outcome of DGK-inhibition on
antitumor immunity of myeloid cells and Tregs remains an open
question.
Concerning effects on cancer cells, contrasting outcomes
are reported for DGK-α and DKG-ζ in the regulation of the
NFκB-pathway, with DGK-α providing activation and DGK-
ζ being inhibitory under inflammatory conditions (Tsuchiya
et al., 2015). In such scenario, DGK-α inhibition would be a
preferable intervention. Along this line, another study reported
suppression of oncogenic survival pathways through DGK-α
inhibition causing tumor cell death in vitro and reducing tumor
growth in mice (Dominguez et al., 2013).
Collectively, DGK-inhibition has promising feature for cancer
immunotherapy on multiple levels, re-invigorating T and NK
cells for tumor cell attack, possibly making them resistant to
TGF-ß suppression, and also weakening tumor cells directly.
As DGKs and co-inhibitory surface proteins (PD-1, CTLA-4)
control different steps in the signaling cascade, it is expected
that DGK-inhibition will combine beneficially with current
checkpoint blockade therapies or other immunotherapies.
Further development is needed in the field of specific DGK-
inhibitors (Sakane et al., 2016) and side-by-side comparisons
of DGK-α and DGK-ζ inhibition to delineate the specific
contribution that each of the isoforms might have in the
restoration or maintenance of immune cell function in the tumor
environment.
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